30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

SeaSpine Up +8% in 2Q19 on New Product Launches -



SeaSpine leveraged newer spine and biologics products to grow in the high single digits amid increased case volume in 2Q19.

  • Increased 2019 revenue guidance by $1MM at both the high and low ends, bringing range to $155MM to $157MM
  • Case volume increased by about 10%, but was somewhat offset by low single-digit price decline and procedure mix heavier on low-complexity cases
  • Spine revenue growth driven by new products, particularly the Shoreline and Mariner systems along with NanoMetalene-based products
  • Orthobiologics revenue growth driven by new products such as OsteoStrand Plus
  • Newer products accounted for 55% of spine revenue and 20% of orthobiologics revenue
  • Mariner Outrigger Revision system and Shoreline cervical interbody implant are both in limited commercial launch, while OsteoCurrent ceramic bone graft substitute and Regatta Lateral System are in full commercial launch
  • Company marked the 20,000th implant of the NanoMetalene interbody device
  • Products treating complex pathologies and deformities posted lower than expected revenue, though leadership believes new product introductions will turn the franchise around starting late in the second half


Performance by Segment

ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):

  2Q19 2Q18 $ Chg % Chg
Spine $19.3 $17.8 $1.5 8.4%
Orthobiologics $20.1 $18.6 $1.4 7.6%
Total $39.3 $36.4 $2.9 8.0%
  1H19 1H18 $ Chg % Chg
Spine $36.4 $33.0 $3.4 10.3%
Orthobiologics $39.1 $36.6 $2.4 6.7%
Total $75.5 $69.6 $5.8 8.4%


Sales by Geographic Region

ORTHOWORLD estimates geographic sales and growth as follows ($MM):

  2Q19 2Q18 $ Chg % Chg
US $35.1 $32.6 $2.4 7.5%
Ex-US $4.2 $3.8 $0.5 12.3%
Total $39.3 $36.4 $2.9 8.0%


Net Earnings Data

Net earnings, inclusive of all revenue, are as follows.

  Amt % of Sales
Sales $39.3  
   Cost of Sales -$14.3 36.4%
   Selling and Admin -$27.6 70.2%
   R & D -$3.6 9.1%
   Other -$5.8 14.8%
Net Earnings -$12.0 -30.6%


Sources: SeaSpine

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.